Prolactin Is an Autocrine or Paracrine Growth Factor for Human Myometrial and Leiomyoma Cells
article
OA: closed
CC0
⤵ 11 in-corpus citations
AI-generated summary
Prolactin was found to promote growth of human myometrial and leiomyoma cells through autocrine or paracrine signaling via its receptor.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: To test the hypothesis that prolactin (PRL) acts as a mitogenic growth factor for human leiomyoma and myometrial cells. METHODS: To test this hypothesis, we performed three different types of experiments. First, we assessed whether exogenous PRL acted as a mitogen for cultured uterine smooth muscle cells. Second, we examined the role of endogenous PRL by assessing the cell number after exposure of the cultures to a neutralizing antibody to PRL. Finally, we examined both fresh tissues and cultured cells for expression of the PRL receptor messenger ribonucleic acid using the techniques of reverse-transcriptase polymerase chain reaction and Southern blotting. RESULTS: A significant suppression in cell number was seen after 5 days of culture for leiomyoma cells but not for myometrial cells after treatment with exogenous PRL. Both cell types showed a significant decrease in cell number after treatment with anti-PRL antibody. A 893-bp segment consistent with the cytoplasmic domain of the long form of the PRL receptor was amplified from both fresh and cultured tissues and confirmed by Southern blotting and sequencing. CONCLUSIONS: PRL appears to be an autocrine or paracrine growth factor for both leiomyoma and myometrial cells. However, there are some differences between tissues in their sensitivity to this growth factor.
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (19)
- doi:10.1016/s0021-9258(18)53332-9 via openalex
- doi:10.1210/edrv-12-3-235 via openalex
- W21534978 via openalex
- doi:10.1016/0002-9378(83)90441-6 via openalex
- doi:10.1210/endo-112-3-1133 via openalex
- doi:10.1002/jcp.1041480116 via openalex
- doi:10.1016/s0021-9258(18)54897-3 via openalex
- doi:10.1016/s0002-9378(94)70247-0 via openalex
- doi:10.1016/0002-9378(88)90083-x via openalex
- doi:10.1210/endo.135.4.7925093 via openalex
- doi:10.1021/bi00591a005 via openalex
- doi:10.1016/s0015-0282(16)58324-1 via openalex
- doi:10.1016/0024-3205(78)90557-x via openalex
- doi:10.1210/jcem.76.5.8496322 via openalex
- doi:10.1095/biolreprod49.6.1149 via openalex
- doi:10.1210/endo-129-1-158 via openalex
- doi:10.1210/jcem.81.1.8550784 via openalex
- doi:10.1210/endo.130.3.1537278 via openalex
- doi:10.1210/mend-3-9-1455 via openalex
Cited by (11)
- Bromocriptine inhibits proliferation in the endometrium from women with adenomyosis 2023
- Unveiling the Pathogenesis of Adenomyosis through Animal Models 2022
- Vascular biology of uterine fibroids: connecting fibroids and vascular disorders 2021
- The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology 2020
- Adenomyosis in mice resulting from mechanically or thermally induced endometrial–myometrial interface disruption and its possible prevention 2020
- Vaginal bromocriptine for treatment of adenomyosis: Impact on magnetic resonance imaging and transvaginal ultrasound 2020
- Adenomyosis: Mechanisms and Pathogenesis 2020
- Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: A pilot study 2019
- Benign Uterine Diseases 2019
- Нyperprolactinemia correction in the complex treatment of endometrial hyperplasia 2013
- Understanding adenomyosis: a case control study 2009
Source provenance
- openalex
- last seen: 2026-05-11T06:35:44.859312+00:00
License: CC0
· commercial use OK